Targeting PI3K Remains Complex in Cancer Therapy

Dr. Lewis Cantley discusses targeting the PI3K pathway in breast cancer and the importance of managing ambient insulin levels during therapy.
Source: CancerNetwork - Category: Cancer & Oncology Authors: Source Type: news

Related Links:

Publication date: Available online 13 February 2019Source: Biochimica et Biophysica Acta (BBA) - Reviews on CancerAuthor(s): Sharad S. Singhal, Ravi Salgia, Sulabh Singhal, David Horne, Sanjay AwasthiAbstractBreast cancer (BC) is the most common cancer among women worldwide. Due to its complexity in nature, effective BC treatment can encounter many challenges. The human RALBP1 gene encodes a 76-kDa splice variant protein, RLIP (ral-binding protein1, RalBP1), a stress-protective mercapturic acid pathway (MAP) transporter protein, that also plays a key role in regulating clathrin-dependent endocytosis (CDE) as a Ral effector...
Source: Biochimica et Biophysica Acta (BBA) Reviews on Cancer - Category: Cancer & Oncology Source Type: research
Conclusion: Estimating the burden of chronic toxicities should contribute to enhance rational decision-making on treatments including chemotherapy in patients with low versus high risk of recurrence.Breast Care
Source: Breast Care - Category: Cancer & Oncology Source Type: research
hamed El-Tanani The delivery of anticancer agents to their subcellular sites of action is a significant challenge for effective cancer therapy. Peptides, which are integral to several oncogenic pathways, have significant potential to be utilised as cancer therapeutics due to their selectivity, high potency and lack of normal cell toxicity. Novel Ras protein-Regulator of chromosome condensation 1 (Ran-RCC1) inhibitory peptides designed to interact with Ran, a novel therapeutic target in breast cancer, were delivered by entrapment into polyethylene glycol-poly (lactic-co-glycolic acid) PEG-PLGA polymeric nanoparticles (N...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Researchers from the University of Wisconsin School of Medicine and Public Health have discovered a new way to measure the efficacy or failure of hormone therapy for breast cancer patients. A study detailing the findings was published in the February issue of The Journal of Nuclear Medicine. The findings showed that positron emission tomography (PET) imaging with 18F-fluorofuranylnorprogesterone (18F-FFNP) has been found to successfully measure changes in progesterone receptor (PR) levels resulting from a short-course estrogen treatment, also known as an estradiol challenge. Estrogen-receptor (ER)-positive breast cancer is...
Source: MDDI - Category: Medical Devices Authors: Tags: Imaging Source Type: news
Park M Abstract Understanding the tumor immune microenvironment (TIME) promises to be key for optimal cancer therapy, especially in triple-negative breast cancer (TNBC). Integrating spatial resolution of immune cells with laser capture microdissection gene expression profiles, we defined distinct TIME stratification in TNBC with implications for current therapies, including immune checkpoint blockade. TNBCs with an immunoreactive microenvironment exhibited tumoral infiltration of granzyme B+ CD8+ T cells, a type I interferon signature, elevated expression of multiple immune inhibitory molecules, including IDO, PD-...
Source: Clinical Breast Cancer - Category: Cancer & Oncology Authors: Tags: J Clin Invest Source Type: research
(Society of Nuclear Medicine and Molecular Imaging) Physicians may soon have a new way to measure the efficacy of hormone therapy for breast cancer patients, according to research published in the February issue of The Journal of Nuclear Medicine.
Source: EurekAlert! - Cancer - Category: Cancer & Oncology Source Type: news
Conclusion.In this study, chemotherapy resulted in increased HRrest and tachycardia, as well as decreased blood pressure and hypotension. Anthracyclines, trastuzumab, and left‐sided radiation were associated with HRrest elevations and impairments of HRrecovery, but exercise training at least twice a week appeared to mitigate these changes.Implications for Practice.This study characterized changes in clinically accessible measures with well‐established prognostic value for cardiovascular disease, and investigated associations with cardiotoxic treatments and the positive influence of exercise. The chemotherapy‐related ...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Symptom Management and Supportive Care, Breast Cancer Source Type: research
ConclusionAltogether, our data show the antitumor potential of the CEAA against breast cancer cells in vitro and in vivo. Further research is necessary to better elucidate the pharmacological application of the CEAA in breast cancer therapy.
Source: Journal of Integrative Medicine - Category: Complementary Medicine Source Type: research
Rockville-based MacroGenics Inc. announced positive results Wednesday from late-stage trials of its breast cancer therapy candidate, sending the company ’s stock price soaring nearly 200 percent for the day. The biotech’s margetuximab product — which targets the “HER2” gene, which can feed the growth of cancer cells, specifically in patients with metastatic breast cancer — was found to be safer and better tolerated than Genentech Inc.'s Herceptin, considered a standard treatment today,…
Source: bizjournals.com Health Care News Headlines - Category: Health Management Authors: Source Type: news
Researchers at Johns Hopkins Medicine have developed a PET imaging technique...Read more on AuntMinnie.comRelated Reading: PET's view of tau could explain women's early dementia PET in the paddock New PET tracer could aid melanoma detection PET tracers help guide breast cancer therapies C-11-based PET tracer could benefit arthritis patients
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news
More News: Breast Cancer | Cancer | Cancer & Oncology | Cancer Therapy | Insulin